Fig. 3From: Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainPSA results. Incremental cost-effectiveness plane. The deterministic results of the base case are shown with a dark filled dot. QALY quality-adjusted life yearBack to article page